25 results on '"Dotan, Efrat"'
Search Results
2. Cardiovascular Concerns, Cancer Treatment, and Biological and Chronological Aging in Cancer: JACC Family Series
- Author
-
Ioffe, Dina, Bhatia-Patel, Sanjana C., Gandhi, Sakshi, Hamad, Eman A., and Dotan, Efrat
- Published
- 2024
- Full Text
- View/download PDF
3. Survival and Toxicity in Patients With Unresectable or Inoperable Biliary Tract Cancers With Ablative Radiation Therapy Versus Nonablative Chemoradiation
- Author
-
Yankey, Hilario, Ruth, Karen J., Dotan, Efrat, Reddy, Sanjay, and Meyer, Joshua E.
- Published
- 2024
- Full Text
- View/download PDF
4. Pembrolizumab monotherapy in patients with previously treated metastatic high-grade neuroendocrine neoplasms: joint analysis of two prospective, non-randomised trials
- Author
-
Vijayvergia, Namrata, Dasari, Arvind, Deng, Mengying, Litwin, Samuel, Al-Toubah, Taymeyah, Alpaugh, R. Katherine, Dotan, Efrat, Hall, Michael J., Ross, Nicole M., Runyen, Melissa M., Denlinger, Crystal S., Halperin, Daniel M., Cohen, Steven J., Engstrom, Paul F., and Strosberg, Jonathan R.
- Published
- 2020
- Full Text
- View/download PDF
5. Disparities in care of older adults of color with cancer: A narrative review.
- Author
-
Dotan, Efrat, Lynch, Shannon M., Ryan, Joanne C., and Mitchell, Edith P.
- Subjects
- *
OLDER people , *CANCER patients , *OLDER patients , *RACE , *INSTITUTIONAL racism - Abstract
This review describes the barriers and challenges faced by older adults of color with cancer and highlights methods to improve their overall care. In the next decade, cancer incidence rates are expected to increase in the United States for people aged ≥65 years. A large proportion will be older adults of color who often have worse outcomes than older White patients. Many issues contribute to racial disparities in older adults, including biological factors and social determinants of health (SDOH) related to healthcare access, socioeconomic concerns, systemic racism, mistrust, and the neighborhood where a person lives. These disparities are exacerbated by age‐related challenges often experienced by older adults, such as decreased functional status, impaired cognition, high rates of comorbidities and polypharmacy, poor nutrition, and limited social support. Additionally, underrepresentation of both patients of color and older adults in cancer clinical research results in a lack of adequate data to guide the management of these patients. Use of geriatric assessments (GA) can aid providers in uncovering age‐related concerns and personalizing interventions for older patients. Research demonstrates the ability of GA‐directed care to result in fewer treatment‐related toxicities and improved quality of life, thus supporting the routine incorporation of validated GA into these patients' care. GA can be enhanced by including evaluation of SDOH, which can help healthcare providers understand and address the needs of older adults of color with cancer who face disparities related to their age and race. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
6. Validation of a Molecular Diagnostic Test for Circulating Tumor DNA by Next-Gen Sequencing.
- Author
-
Fernandez, Sandra V., Tan, Yin Fei, Rao, Shilpa, Fittipaldi, Patricia, Sheriff, Fathima, Borghaei, Hossein, Dotan, Efrat, Winn, Jennifer S., Edelman, Martin J., Treat, Joseph, Judd, Julia, Alpaugh, R. Katherine, Wang, Y. Lynn, Yu, Jian Q., Wasik, Mariusz, and Baldwin, Don A.
- Subjects
CIRCULATING tumor DNA ,SINGLE nucleotide polymorphisms ,DNA sequencing ,DIAGNOSIS methods ,GENE frequency ,DNA insertion elements ,MOLECULAR diagnosis - Abstract
A modified version of the PGDx elio
TM Plasma Resolve assay was validated as a laboratory-developed test (LDT) for clinical use in the Molecular Diagnostics Laboratory at Fox Chase Cancer Center. The test detects single nucleotide variants (SNVs) and small insertions and deletions (indels) in 33 target genes using fragmented genomic DNA extracted from plasma. The analytical performance of this assay was assessed with reference standard DNA and 29 samples from cancer patients and detected 66 SNVs and 23 indels. Using 50 ng of input DNA, the sensitivity was 95.5% to detect SNVs at 0.5% allele frequency, and the specificity was 92.3%. The sensitivity to detect indels at 1% allele frequency was 70.4%. A cutoff of 0.25% variant allele frequency (VAF) was set up for diagnostic reporting. An inter-laboratory study of concordance with an orthologous test resulted in a positive percent agreement (PPA) of 91.7%. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
7. Understanding the Challenges Faced by Esophageal and Gastroesophageal Junction Cancer Survivors.
- Author
-
McGillivray, Erin, Jain, Rishi, Ramamurthy, Chethan, Sheng, Jennifer Y., Granina, Evgenia, Yu, Daohai, Lu, Xiaoning, Abbas, Abbas E., Dotan, Efrat, Meyer, Joshua E., Fang, Carolyn Y., and Denlinger, Crystal S.
- Subjects
COUGH -- Risk factors ,RESPIRATORY obstructions -- Risk factors ,CANCER patient psychology ,STOMACH tumors ,STATISTICS ,CROSS-sectional method ,ACQUISITION of data ,FISHER exact test ,HEALTH status indicators ,DEGLUTITION disorders ,PATIENTS' attitudes ,SURVEYS ,GASTROESOPHAGEAL reflux ,QUALITY of life ,QUESTIONNAIRES ,MEDICAL records ,HEALTH behavior ,RESEARCH funding ,DATA analysis ,SOCIAL skills ,OPIOID analgesics ,ESOPHAGEAL tumors ,DISEASE risk factors - Abstract
The primary aim of this study is to characterize long-term quality of life (QOL) in patients with esophageal and gastroesophageal junction (EGEJ) cancers who underwent curative intent treatment. EGEJ survivors were recruited to participate in a one-time cross-sectional survey study using validated questionnaires assessing QOL. Chart review was conducted for patient demographics and clinical characteristics. Spearman correlation coefficients, Wilcoxon signed-rank test, and Fisher's exact test were used to assess relationships between patient characteristics and long-term outcomes. QOL was relatively high in this sample, as evidenced by high median scores on the functional scales and low median scores in the symptom domains of the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-C30, with an overall median global health score of 75.0 (range 66.7-83.3). Patients using opiates at the time of survey reported lower role functioning (P =.004), social functioning (P =.052), and overall global health (P =.041). Younger patients had significantly higher rates of reflux (P =.019), odynophagia (P =.045), choking (P =.005), and cough (P =.007). Patients using opiates or of younger age had lower QOL and higher symptoms in this cohort of long-term EGEJ survivors. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
8. Assessing Oncologists' Adoption of Biomarker Testing in Metastatic Colorectal Cancer Using Real-World Data.
- Author
-
Iyer, Pritish, Deng, Mengying, Handorf, Elizabeth A, Nakhoda, Shazia, and Dotan, Efrat
- Subjects
ONCOLOGISTS ,COLORECTAL cancer ,BIOMARKERS - Abstract
Background Despite national guideline recommendations for universal biomarker testing (KRAS , NRAS , BRAF , and mismatch repair and microsatellite instability [MMR/MSI]) in all patients with metastatic colorectal cancer (mCRC), little is known regarding adherence to these recommendations in routine practice. Methods We retrospectively reviewed patients with mCRC diagnosed between January 1, 2013, and December 27, 2018, from a de-identified electronic health record–derived database. We analyzed disparities in KRAS , NRAS , BRAF , and MMR/MSI testing by race, age, sex, and insurance status using χ
2 tests and t tests. We evaluated changes in biomarker testing over time with attention to changes around dates of landmark publications and guideline updates using χ2 tests and Cochran-Armitage tests. Results A total of 20 333 patients were identified of which 66.6% had test results for any biomarker. Rates of test results for all 4 biomarkers statistically significantly increased over time (P < .001). However, as of June 30, 2018, the rate of test results was only 46% for NRAS , 56% for KRAS , and 46% for BRAF. As of December 31, 2017, the rate of MMR/MSI testing was 59%. Higher documented testing rates were associated with younger age, lower Eastern Cooperative Oncology Group performance status, and commercial insurance. There were no clinically meaningful and/or statistically significant differences in documented testing rates by tumor sidedness, race, sex, or initial stage. Conclusions Increased rates of documented testing for NRAS , BRAF , and MMR/MSI in mCRC was seen between 2013 and 2018 reflecting adoption of guideline recommendations. However, the rate of documented testing remains lower than expected and warrants additional research to understand the extent to which this may represent a clinical practice quality concern. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
9. Trial Design Considerations to Increase Older Adult Accrual to National Cancer Institute Clinical Trials.
- Author
-
Le-Rademacher, Jennifer, Mohile, Supriya, Unger, Joseph, Hudson, Matthew F, Foster, Jared, Lichtman, Stuart, Perlmutter, Jane, Dotan, Efrat, Extermann, Martine, Dodd, Kevin, Tew, William, Klepin, Heidi, Wildes, Tanya M, Sedrak, Mina S, Jatoi, Aminah, and Little, Richard F
- Published
- 2022
- Full Text
- View/download PDF
10. Paraneoplastic limbic encephalitis following treatment with single-agent pembrolizumab for advanced gastroesophageal adenocarcinoma.
- Author
-
Laderman, Lauren, Naveed, Omer, LoPinto-Khoury, Carla, Dotan, Efrat, and Miron, Benjamin
- Abstract
The use of immune checkpoint inhibitors is increasing in clinical practice. While they have provided significant benefit to many patients, a new category of adverse effects, immune-related adverse effects, has emerged with their use. These effects can range from mild to severe and affect nearly every organ system. A man in his 70swith metastatic gastro-oesophageal junction adenocarcinoma who received one cycle of third-line pembrolizumab presented after three episodes of transient left facial paresthesia, the last of which extended to the left extremities and disturbed peripheral vision of the left eye. He was found to have subclinical seizures and cerebrospinal fluid positive for Ma2/Ta paraneoplastic antibodies, consistent with paraneoplastic limbic encephalitis. We describe an unusual presentation of paraneoplastic limbic encephalitis. This case adds to the limited literature describing the association of paraneoplastic limbic encephalitis and treatment with immune checkpoint inhibitors as well as the observed associations with immune-related adverse events and treatment responses. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
11. Circulating Tumor DNA in Precision Oncology and Its Applications in Colorectal Cancer.
- Author
-
Arisi, Maria F., Dotan, Efrat, and Fernandez, Sandra V.
- Subjects
- *
CIRCULATING tumor DNA , *COLORECTAL cancer , *CELL-free DNA , *COMPUTED tomography - Abstract
Circulating tumor DNA (ctDNA) is a component of cell-free DNA (cfDNA) that is shed by malignant tumors into the bloodstream and other bodily fluids. ctDNA can comprise up to 10% of a patient's cfDNA depending on their tumor type and burden. The short half-life of ctDNA ensures that its detection captures tumor burden in real-time and offers a non-invasive method of repeatedly evaluating the genomic profile of a patient's tumor. A challenge in ctDNA detection includes clonal hematopoiesis of indeterminate potential (CHIP), which can be distinguished from tumor variants using a paired whole-blood control. Most assays for ctDNA quantification rely on measurements of somatic variant allele frequency (VAF), which is a mutation-dependent method. Patients with certain types of solid tumors, including colorectal cancer (CRC), can have levels of cfDNA 50 times higher than healthy patients. ctDNA undergoes a precipitous drop shortly after tumor resection and therapy, and rising levels can foreshadow radiologic recurrence on the order of months. The amount of tumor bulk required for ctDNA detection is lower than that for computed tomography (CT) scan detection, with ctDNA detection preceding radiologic recurrence in many cases. cfDNA/ctDNA can be used for tumor molecular profiling to identify resistance mutations when tumor biopsy is not available, to detect minimal residual disease (MRD), to monitor therapy response, and for the detection of tumor relapse. Although ctDNA is not yet implemented in clinical practice, studies are ongoing to define the appropriate way to use it as a tool in the clinic. In this review article, we examine the general aspects of ctDNA, its status as a biomarker, and its role in the management of early (II–III) and late (IV; mCRC) stage colorectal cancer (CRC). [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
12. Impact of the COVID-19 Pandemic on Treatment Patterns for Patients With Metastatic Solid Cancer in the United States.
- Author
-
Parikh, Ravi B, Takvorian, Samuel U, Vader, Daniel, Wileyto, E Paul, Clark, Amy S, Lee, Daniel J, Goyal, Gaurav, Rocque, Gabrielle B, Dotan, Efrat, Geynisman, Daniel M, Phull, Pooja, Spiess, Philippe E, Kim, Roger Y, Davidoff, Amy J, Gross, Cary P, Neparidze, Natalia, Miksad, Rebecca A, Calip, Gregory S, Hearn, Caleb M, and Ferrell, Will
- Abstract
Background The COVID-19 pandemic has led to delays in patients seeking care for life-threatening conditions; however, its impact on treatment patterns for patients with metastatic cancer is unknown. We assessed the COVID-19 pandemic's impact on time to treatment initiation (TTI) and treatment selection for patients newly diagnosed with metastatic solid cancer. Methods We used an electronic health record–derived longitudinal database curated via technology-enabled abstraction to identify 14 136 US patients newly diagnosed with de novo or recurrent metastatic solid cancer between January 1 and July 31 in 2019 or 2020. Patients received care at approximately 280 predominantly community-based oncology practices. Controlled interrupted time series analyses assessed the impact of the COVID-19 pandemic period (April-July 2020) on TTI, defined as the number of days from metastatic diagnosis to receipt of first-line systemic therapy, and use of myelosuppressive therapy. Results The adjusted probability of treatment within 30 days of diagnosis was similar across periods (January-March 2019 = 41.7%, 95% confidence interval [CI] = 32.2% to 51.1%; April-July 2019 = 42.6%, 95% CI = 32.4% to 52.7%; January-March 2020 = 44.5%, 95% CI = 30.4% to 58.6%; April-July 2020 = 46.8%, 95% CI= 34.6% to 59.0%; adjusted percentage-point difference-in-differences = 1.4%, 95% CI = −2.7% to 5.5%). Among 5962 patients who received first-line systemic therapy, there was no association between the pandemic period and use of myelosuppressive therapy (adjusted percentage-point difference-in-differences = 1.6%, 95% CI = −2.6% to 5.8%). There was no meaningful effect modification by cancer type, race, or age. Conclusions Despite known pandemic-related delays in surveillance and diagnosis, the COVID-19 pandemic did not affect TTI or treatment selection for patients with metastatic solid cancers. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
13. Prospective Comparison of Geriatric Assessment and Provider's Assessment of Older Adults With Metastatic Breast Cancer in the Community.
- Author
-
Seedor, Rino S, Meeker, Caitlin R, Lewis, Bianca, Handorf, Elizabeth A, Filchner, Kelly A, Varadarajan, Ramya, Hensold, Jack, Padmanabhan, Aruna, Negin, Benjamin, Blankstein, Kenneth, Chawla, Neha R, Song, Wei (Frank), Epstein, Jessica, Winn, Jennifer, Goldstein, Lori J, and Dotan, Efrat
- Subjects
SOCIAL support ,FUNCTIONAL status ,GERIATRIC assessment ,METASTASIS ,COMMUNITY health services ,PHYSICAL fitness ,DIET ,COGNITION ,CANCER patients ,DESCRIPTIVE statistics ,MEDICAL needs assessment ,BREAST tumors ,LONGITUDINAL method - Abstract
Background Geriatric assessment (GA) is recommended for evaluating fitness of an older adult with cancer. Our objective was to prospectively evaluate the gaps that exist in the assessment of older adults with metastatic breast cancer (OA-MBC) in community practices (CP). Methods Self-administered GA was compared to provider's assessment (PA) of patients living with MBC aged ≥65 years treated in CP Providers were blinded to the GA results until PA was completed. McNemar's test was used to detect differences between PA and GA. Results One hundred patients were enrolled across 9 CP (median age 73.9). Geriatric assessment detected a total of 356 abnormalities in 96 patients; of which, 223 required interventions. African American and widowed/single patients were more likely to have abnormalities identified by GA. On average, across 100 patients, PA did not detect 25.5% of GA-detected abnormalities, mostly in functional status, social support, nutrition, and cognition. These differences were less pronounced among providers with more clinical experience. Patients with abnormal Timed Up and Go tests more likely had additional abnormalities in other domains, and more abnormalities that were not identified by PA. Providers were "surprised" by GA results in 33% of cases, mainly with cognitive or social support findings, and reported plans for management change for 39% of patients based on GA findings. Conclusions Including a GA in the care of OA-MBC in CP is beneficial for the detection of multiple abnormalities not detected by routine PA. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
14. Optimal Management of Patients with Advanced or Metastatic Cholangiocarcinoma: An Evidence-Based Review.
- Author
-
Ioffe, Dina, Phull, Pooja, and Dotan, Efrat
- Subjects
CHOLANGIOCARCINOMA ,BILIARY tract ,DIAGNOSIS ,PROGNOSIS ,TUMOR classification - Abstract
Cholangiocarcinomas are rare tumors originating at any point along the biliary tree. These tumors often pose significant challenges for diagnosis and treatment, and often carry a poor prognosis. However, in recent years, studies have identified significant molecular heterogeneity with up to 50% of tumors having detectable mutations, leading to the guideline recommendations for molecular testing as part of the diagnostic workup for these tumors. In addition, better classification of these tumors and understanding of their biology has led to new drugs being approved for treatment of this resistant tumor. This manuscript will provide a comprehensive review of the epidemiology, risk factors, diagnostic approach, molecular classification, and treatment options for patients with advanced cholangiocarcinomas. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
15. Dosing Schedules of Gemcitabine and nab-Paclitaxel for Older Adults With Metastatic Pancreatic Cancer.
- Author
-
Winer, Arthur, Handorf, Elizabeth, and Dotan, Efrat
- Subjects
GEMCITABINE ,PACLITAXEL ,PANCREATIC cancer - Abstract
Background Gemcitabine and nab-paclitaxel (GA) is a first-line treatment for patients with metastatic pancreatic cancer (mPDAC). The traditional dosing schedule of GA is days 1, 8, and 15 of a 28-day cycle. Frequently, older adults are given a modified dosing schedule using 2 doses per cycle because of toxicity. We retrospectively analyzed treatment patterns and outcomes of older adults with mPDAC given these 2 dosing schedules. Methods Patients 65 years or older with mPDAC treated with GA in a nationwide real-world database between January 1, 2014, and May 31, 2019, were included. Demographic, disease, and treatment information were collected. Patients were grouped by dosing at treatment initiation (traditional vs modified dosing schedules). Endpoints were time on treatment (TOT) and overall survival (OS) in patients receiving at least 2 cycles. All statistical tests were 2-sided. Results 1317 patients were included (traditional dosing schedule: n = 842; modified dosing schedule: n = 475). Median age at diagnosis was 72 and 73 years for traditional and modified dosing schedules, respectively (P <.001), but sex, race, and performance status were not statistically significantly different. The median TOT and OS were better for the traditional vs modified dosing schedule (unadjusted median TOT, first-line = 4.18 vs 3.26 mo, P =.04; OS = 9.44 vs 7.63 mo, P =.003). Conclusion In this real-world cohort, treatment of older mPDAC patients with a modified dosing schedule of GA resulted in shorter TOT and worse OS vs a traditional dosing schedule. With the caveats of potential confounding that exist in a nonrandomized retrospective database, these results suggest that dose intensity may be important, and prospective studies are necessary to ensure we treat our patients most effectively. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
16. Paclitaxel With or Without Cixutumumab as Second-Line Treatment of Metastatic Esophageal or Gastroesophageal Junction Cancer: A Randomized Phase II ECOG-ACRIN Trial.
- Author
-
Stockton, Shannon, Catalano, Paul, Cohen, Steven J, Burtness, Barbara A, Mitchell, Edith P, Dotan, Efrat, Lubner, Sam J, Kumar, Pankaj, Mulcahy, Mary F, Fisher Jr., George A, Crandall, Theodore L, and Benson, Al
- Subjects
THERAPEUTIC use of antineoplastic agents ,DRUG efficacy ,SOMATOMEDIN ,COMBINATION drug therapy ,CONFIDENCE intervals ,DRUG tolerance ,METASTASIS ,RANDOMIZED controlled trials ,TREATMENT effectiveness ,DESCRIPTIVE statistics ,PACLITAXEL ,STATISTICAL sampling ,PROGRESSION-free survival ,ESOPHAGEAL tumors ,OVERALL survival ,EVALUATION - Abstract
Background: Patients with advanced esophageal cancer carry poor prognoses; limited data exist to guide second-line therapy in the metastatic setting. Paclitaxel has been used yet is associated with limited efficacy. There is preclinical evidence of synergy between paclitaxel and cixutumumab, a monoclonal antibody targeting insulin-like growth factor-1 receptor. We conducted a randomized phase II trial of paclitaxel (arm A) versus paclitaxel plus cixutumumab (arm B) in the second-line for patients with metastatic esophageal or gastroesophageal junction (GEJ) cancers. Methods: The primary endpoint was progression-free survival (PFS); 87 patients (43 in arm A, 44 in arm B) were treated. Results: Median PFS was 2.6 months in arm A [90% CL 1.8-3.5] and 2.3 months in arm B [90% 2.0-3.5], P =.86. Stable disease was observed in 29 (33%) patients. Objective response rates for Arms A and B were 12% [90% CI, 5-23%] and 14% [90% CI, 6-25%]. Median overall survival was 6.7 months [90% CL 4.9-9.5] in arm A and 7.2 months [90% CL 4.9-8.1] in arm B, P = 56. Conclusion: The addition of cixutumumab to paclitaxel in second-line therapy of metastatic esophageal/GEJ cancer was well tolerated but did not improve clinical outcomes relative to standard of care (ClinicalTrials.gov Identifier: NCT01142388). Paclitaxel has been used for second-line treatment of esophageal cancer, with limited efficacy. Considering the preclinical evidence of synergy between paclitaxel and cixutumumab, this randomized phase II trial of paclitaxel (arm A) versus paclitaxel plus cixutumumab (arm B) was conducted. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
17. Physical Activity and Outcomes in Patients with Stage III Colon Cancer: A Correlative Analysis of Phase III Trial NCCTG N0147 (Alliance).
- Author
-
Phipps, Amanda I., Qian Shi, Zemla, Tyler J., Dotan, Efrat, Gill, Sharlene, Goldberg, Richard M., Hardikar, Sheetal, Jahagirdar, Balkrishna, Limburg, Paul J., Newcomb, Polly A., Shields, Anthony, Sinicrope, Frank A., Sargent, Daniel J., and Alberts, Steven R.
- Abstract
Background: Prior studies have supported an inverse association between physical activity and colon cancer risk and suggest that higher physical activity may also improve cancer survival. Among participants in a phase III adjuvant trial for stage III colon cancer, we assessed the association of physical activity around the time of cancer diagnosis with subsequent outcomes. Methods: Before treatment arm randomization (FOLFOX or FOLFOX + cetuximab), study participants completed a questionnaire including items regarding usual daily activity level and frequency of participation in recreational physical activity (N = 1,992). Using multivariable Cox models, we calculated HRs for associations of aspects of physical activity with disease-free (DFS) and overall survival (OS). Results: Over follow-up, 505 participants died and 541 experienced a recurrence. Overall, 75% of participants reported recreational physical activity at least several times a month; for participants who reported physical activity at least that often (vs. once a month or less), the HRs for DFS and OS were 0.82 [95% confidence interval (CI), 0.69-0.99] and 0.76 (95% CI, 0.63-0.93), respectively. There was no evidence of material effect modification in these associations by patient or tumor attributes, except that physical activity was more strongly inversely associated with OS in patients with stage T3 versus T4 tumors (P
interaction = 0.03). Conclusions: These findings suggest that higher physical activity around the time of colon cancer diagnosis may be associated with more favorable colon cancer outcomes. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
18. Tu1425 PRE-OPERATIVE WEIGHT LOSS - FRIEND OR FOE IN PATIENTS UNDERGOING MAJOR PANCREATIC RESECTION? AN ACS-NSQIP ANALYSIS.
- Author
-
Crocker, Andrew B., Azim, Asad, Dotan, Efrat, Meyer, Joshua, Astsaturov, Igor, and Reddy, Sanjay S.
- Published
- 2023
- Full Text
- View/download PDF
19. Adjusting Our Current Practice to Better Care for the Older Patient With Cancer.
- Author
-
Dotan, Efrat
- Subjects
- *
ELDER care , *GERIATRIC assessment , *CANCER patient medical care , *HEALTH care teams , *NURSE practitioners - Abstract
The article addresses the challenges associated with caring for an older patient with cancer. Topics include the projected increase in the number of older people with cancer by 2050, obstacles and concerns that arise at different stages of the disease according to an article by A. Shahrokni and colleagues, and a model proposed by Shahrokni et al for the identification of geriatric syndromes and referral to support services.
- Published
- 2017
- Full Text
- View/download PDF
20. Oncologists' Response to New Data Regarding the Use of Epidermal Growth Factor Receptor Inhibitors in Colorectal Cancer.
- Author
-
Dotan, Efrat, Tianyu Li, Hall, Michael J., Meropol, Neal J., Beck, J. Robert, and Yu-Ning Wong
- Subjects
- *
THERAPEUTIC use of monoclonal antibodies , *ALGORITHMS , *BIOMARKERS , *CHI-squared test , *COLON tumors , *DRUG utilization , *EPIDERMAL growth factor , *MEDICAL protocols , *RESEARCH funding , *LOGISTIC regression analysis , *MULTIPLE regression analysis , *RETROSPECTIVE studies , *DATA analysis software , *DESCRIPTIVE statistics , *CHEMICAL inhibitors ,RECTUM tumors - Abstract
Purpose: Although initially approved for metastatic colorectal cancer (mCRC) tumors with epidermal growth factor receptor (EGFR) overexpression, the use of anti-EGFR antibodies is now restricted to wild-type KRAS tumors. Little is known about prescribers' response to new clinical data, practice guidelines, and US Food and Drug Administration (FDA) label change with regard to the use of anti-EGFR antibodies in clinical practice. Methods: Commercially insured patients withmCRCwhoreceived second-line therapy between 2004 and 2010 were identified by dusing the LifeLink Health Plan Claims Database.We calculated the fraction of patients receiving anti-EGFR antibody in 2-month intervals. χ2 tests were used to compare treatment rates at four time points: time 1: June 2008, ASCO presentation of clinical data; time 2: February 2009, ASCO guidelines publication; time 3: August 2009, FDA label change; time 4: April 2010 to 8 months after FDA label change. Results: Five thousand eighty-nine patients received secondline therapy; of these, 2,599 patients received an anti-EGFR antibody. Median age was 60 years (range, 20 to 97), with 57% male sex. The majority of patients (59.4%) received an anti-EGFR antibody at time 1, with significant decrease at each of the subsequent time points (time 2: 46.2% [P=.019]; time 3: 35.2% [P<.001]; Time 4: 16.2% [P<.001]). Multivariable logistic regression did not show any affect of age, sex, comorbidities, or region of the country on this pattern. Conclusions: The use of anti-EGFR antibodies for mCRC decreased after the presentation of clinical trial data, ASCO guidelines publication, and FDA label change. These data suggest that oncologists respond rapidly to new evidence and professional guidelines, and readily incorporate predictive biomarkers into clinical practice. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
21. Impact of Rituximab (Rituxan) on the Treatment of B-Cell Non-Hodgkin's Lymphoma.
- Author
-
Dotan E, Aggarwal C, Smith MR, Dotan, Efrat, Aggarwal, Charu, and Smith, Mitchell R
- Abstract
Non-Hodgkin's lymphoma (NHL) is the most common hematological malignancy in adults, with B-cell lymphomas accounting for 85% of all NHLs. The most substantial advancement in the treatment of B-cell malignancies, since the advent of combination chemotherapy, has been the addition of the monoclonal anti-CD20 antibody rituximab (Rituxan). Since its initially reported single-agent activity in indolent lymphomas in 1997, the role of rituximab has expanded to cover both indolent and aggressive lymphomas.This article focuses on the impact of rituximab on the treatment, survival, and long-term outcomes of patients with indolent and aggressive lymphomas over the past two decades. [ABSTRACT FROM AUTHOR]
- Published
- 2010
22. Circulating Tumor Cells: Evolving Evidence and Future Challenges.
- Author
-
DOTAN, EFRAT, COHEN, STEVEN J., ALPAUGH, KATHERINE R., and MEROPOL, NEAL J.
- Subjects
CANCER cells ,ONCOLOGY ,COLON cancer ,BREAST cancer ,BIOMARKERS - Abstract
Circulating tumor cells (CTCs) are rare malignant cells found in the peripheral blood that originate from the primary tumor or metastatic sites. New techniques have been developed to isolate and characterize these cells. CTC enumeration has been incorporated into different fields of oncology as a prognostic marker, a tool to monitor therapy response, and a method to understand basic tumor characteristics. This review covers the different techniques available for isolation of CTCs, the clinical utility of CTCs in breast, prostate, and colon cancer, and future directions in this field. The Oncologist 2009;14:1070-1082 [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
23. Impact of Immunoscore on the Management of Stage II Colon Cancer Patients: A Physician Survey.
- Author
-
Kasi, Anup, Dotan, Efrat, Poage, Graham M., Catteau, Aurelie, Vernerey, Dewi, George, Manju, and Barzi, Afsaneh
- Subjects
- *
COLON tumors , *CANCER chemotherapy , *SURVEYS , *TUMOR classification , *TREATMENT effectiveness , *CASE studies , *DECISION making in clinical medicine , *ONCOLOGISTS - Abstract
Simple Summary: Selection of appropriate stage II colon cancer patients for adjuvant chemotherapy (AC) is controversial. A novel immune response classifier has previously been validated to refine patient selection, but its impact on oncologist treatment planning had yet to be described. In this survey, all but one oncologist altered clinical practice recommendations, and recommendations for AC prescriptions were reduced by half (among the Immunoscore-high cases (low recurrence risk)). This study revealed that the Immunoscore results could significantly decrease AC use in patients with stage II colon cancer who may not benefit from it, thereby reducing the administration of nonvalue care. Background: Adjuvant chemotherapy use in stage II colon cancer is controversial. Current prognostic risk factors do not take the tumor immune microenvironment into account. Consideration of the Immunoscore, which measures the host immune response at the tumor site, may assist clinicians in reducing adjuvant chemotherapy use in patients who are unlikely to benefit from it. This study sought to determine the potential clinical utility of the Immunoscore, via its effect on medical oncologists' recommendations for management of patients with stage II colon cancer. Methods: De-identified vignettes of 10 patients with stage II colon cancer were presented to 25 practicing medical oncologists. Each participant completed surveys indicating recommendations for adjuvant chemotherapy and surveillance strategies. An educational session was subsequently conducted, and the same patient profiles were re-presented but included immunoscore results. Participants were again asked to provide their recommendations. A participant was counted as influenced if their responses were altered after immunoscore test results were provided. Results: All but one participant (96%) altered a management recommendation for ≥1 case. For individual cases, a mean of 55% (range, 40–80%) of participants altered their recommendations for adjuvant chemotherapy and/or surveillance. For the immunoscore-high cases (low-risk of recurrence), recommendations for adjuvant chemotherapy use decreased from 60% to 31%. Conclusions: These results indicate a willingness by oncologists to integrate immunoscore information into clinical practice recommendations. Incorporation of immunoscore data resulted in the reduction of nonvalue care in the simulated population. Confirmation in prospective studies is planned. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
24. Impact of Clinical Markers of Nutritional Status and Feeding Jejunostomy Use on Outcomes in Esophageal Cancer Patients Undergoing Neoadjuvant Chemoradiotherapy.
- Author
-
Jain, Rishi, Shaikh, Talha, Yee, Jia-Llon, Au, Cherry, Denlinger, Crystal S., Handorf, Elizabeth, Meyer, Joshua E., and Dotan, Efrat
- Abstract
Background: Patients with esophageal cancer (EC) have high rates of malnutrition due to tumor location and treatment-related toxicity. Various strategies are used to improve nutritional status in patients with EC including oral and enteral support. Methods: We conducted a retrospective analysis to determine the impact of malnutrition and prophylactic feeding jejunostomy tube (FJT) placement on toxicity and outcomes in patients with localized EC who were treated with neoadjuvant chemoradiation therapy (nCRT) followed by esophagectomy. Results: We identified 125 patients who were treated with nCRT between 2002 and 2014. Weight loss and hypoalbuminemia occurred frequently during nCRT and were associated with multiple adverse toxicity outcomes including hematologic toxicity, nonhematologic toxicity, grade ≥3 toxicity, and hospitalizations. After adjusting for relevant covariates including the specific nCRT chemotherapy regimen received and the onset of toxicity, there were no significant associations between hypoalbuminemia, weight loss, or FJT placement and relapse-free survival (RFS) or overall survival (OS). FJT placement was associated with less weight loss during nCRT (p = 0.003) but was not associated with reduced toxicity or improved survival. Conclusions: Weight and albumin loss during nCRT for EC are important factors relating to treatment toxicity but not RFS or OS. While pretreatment FJT placement may reduce weight loss, it may not impact treatment tolerance or survival. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
25. Hematology-Oncology Fellows' Training in Geriatrics and Geriatric Oncology: Findings From an American Society of Clinical Oncology-Sponsored National Survey.
- Author
-
Maggiore, Ronald J., Dale, William, Hurria, Arti, Klepin, Heidi D., Chapman, Andrew, Dotan, Efrat, Mohile, Supriya G., Naeim, Arash, Gajra, Ajeet, and Buss, Mary K.
- Subjects
- *
ELDER care , *CANCER patient medical care , *HEMATOLOGY , *MEDICAL education , *STATISTICAL sampling , *SCHOLARSHIPS , *SURVEYS , *DATA analysis software , *PHYSICIANS' attitudes , *DESCRIPTIVE statistics - Abstract
Purpose Older adults compose the majority of patients with cancer in the United States; however, it is unclear how well geriatrics or geriatric oncology training is being incorporated into hematology-oncology (hem-onc) fellowships. Methods A convenience sample of hem-onc fellows completed a (written or electronic) survey assessing their education, clinical experiences, and perceived proficiency in geriatric oncology during training; knowledge base in geriatric oncology; confidence in managing older adults with cancer; and general attitudes toward geriatric oncology principles. Results Forty-five percent of respondents (N = 138) were female, 67% were based in the United States, and most (60%) were past their first year of training. Most fellows rated geriatric oncology as important or very important (84%); however, only 25% reported having access to a geriatric oncology clinic and more than one half (53%) reported no lectures in geriatric oncology. Fellows reported fewer educational experiences in geriatric oncology than in nongeriatric oncology. For example, among procedure-based activities, 12% learned how to perform a geriatric assessment but 78% learned how to perform a bone marrow biopsy (P , .05). Of those completing the knowledge-based items, 41% were able to identify correctly the predictors of chemotherapy toxicity in older adults with cancer. Conclusion Despite the prevalence of cancer in older adults, hem-onc fellows report limited education in or exposure to geriatric oncology. The high value fellows place on geriatric oncology suggests that they would be receptive to additional training in this area. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.